Inspire(US:INSP) Prnewswire·2025-11-14 15:26Core Viewpoint - Inspire Medical Systems is facing legal scrutiny due to allegations of misleading investors regarding the demand and launch of its Inspire V device, leading to significant financial losses for investors [3][4]. Company Overview - Inspire Medical Systems, Inc. is under investigation by Faruqi & Faruqi, LLP for potential violations of federal securities laws [1][3]. - The company has been accused of making false statements about the market demand for its Inspire V device and the necessary steps taken for its launch [3]. Recent Developments - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device, citing that treatment centers had not completed required training and onboarding [4]. - The company also faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025 [4]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a drastic cut in its 2025 earnings guidance by over 80% [5]. Financial Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [5]. Legal Proceedings - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [1][6]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [6].